Having exceeded 140p in February, shares in self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) last closed at 112.5p and are currently further lower on the back of 2020 results announcement. So what’s the detail?...
Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced it “has been granted an EU-wide patent covering the use of its G+® graphene in golf ball applications”. It emphasises this “the first step towards addressing a very large global market” and the shares have responded currently 4% higher to 106p, a £65 million market capitalisation. Is this justified?...
Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) has made a trading update including noting 2020 revenue “further improvement” from previously reported expectations, Q1 2021 revenue expected to be up 20% from the same period last year and that “there is a strong pipeline of opportunities”. Why are the shares though still well down from 145p reached earlier this year?...
A “Successful Absorption Evaluation Test”-titled announcement from Directa Plus (DCTA) re. its pristine graphene nanoplatelets powder through human skin, with it stated “our suite of successful in vitro tests proves to customers in the textile industry that they can safely adopt our products to create exciting new garments enhanced by our graphene products”. Exciting news?...
Directa Plus (DCTA) “is pleased to announce that the company has signed a supply agreement and a Strategic R&D Agreement with NexTech Batteries Inc., a leading company in the field of Lithium Sulphur batteries based in Nevada, US” – and the shares are currently more than 10% higher in response at 144p. So what’s the detail?...
A “Directorate Change”-titled announcement from self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) – and the shares currently at 88.5p, more than 4% lower in response. I guess the change ain’t an exciting new appointment then...
A trading update from Directa Plus (DCTA) includes that the company “finished 2020 with better revenues than expected even at the start of December” – and the shares have currently responded more than 13% higher, above 90p. But revenue is, of course, vanity and the achievement in ‘better than expected’, of course, depends on what the expectations are...
Shares in graphene-based products company Directa Plus (DCTA) are currently at 88.5p, more than 40% higher, on it announcing what it argues “represents the opening of a new, high potential vertical market that could use large amounts of our products”. Is the share price response really justified though?...
An early morning tweet comes to me from an investor in Directa Plus (DCTA) suggesting that, although the share is speculative it is “under the radar screens of AIM tipsters” and insanely cheap. At 83p the Italian-run company is valued at £51 million so I suspect it has already received a good bit more than zero coverage.
Directa Plus (DCTA) is “honoured to be working with Loro Piana to incorporate Directa Plus's innovative G+ Graphene technology into some of their fabrics and garments” – and the shares have responded higher, back above 60p…
Writing on graphene-based products company Directa Plus (DCTA) in September, I reviewed do road test & CEO share purchase merit the shares soaring? – concluding by noting “recent half-year results from the company showed a €1.75 million loss on revenue of just €0.57 million, with net cash down to €4.6 million. The shares have though currently spiked to circa 70p, capitalising the company at more than £30 million. Caveat emptor. Avoid / sell”. At 11:30am today, “Proposed Placing to raise a minimum of £3 million”…
Writing on Directa Plus (DCTA) in September, with the shares up to circa 70p, I questioned do road test & CEO share purchase merit the shares soaring?. Now, an “Environmental Sale and Participation in Trial” announcement today has followed a trading update yesterday…
Writing on graphene-based products company Directa Plus (DCTA) in June I questioned significant commercial progress? The shares have though soared today on “World's First Road Surface Containing Graphene” and “Director/PDMR Shareholding” announcements from the company…
Directa Plus (DCTA) has made an AGM Statement commencing “during 2017 we made significant commercial progress across our four key target markets and I am pleased to report that this momentum has continued into 2018”. Sounds promising…
Graphite play Directa Plus (DCTA) was not one of the better new issues of 2016. Nomad and broker Cantor Fitzerald earned a good few shekels raising it £12.8 million at 75p in May 2016. The shares roofed it to 200p but the crashed to 32p by early August this year. At that point Cantor's decided to earn its shekels as retained broker with analyst William Game (pictured below) upgrading his stance from corporate "hold" to "buy". Paid for rampers Proactive reports:
